Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 448, 400-401 (26 July 2007) | doi:10.1038/448400a; Published online 25 July 2007
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Methods to Analyze Consumer Emotions
The Seeker is looking for methods to analyze consumer emotions. This Challenge requires only a writ...
- More Challenges
- Powered by:
nature jobs
Postdoctoral Position Studying Immunology
- The University of Chicago
- Chicago, IL
Tenure-Track Faculty Positions
- The University of Texas Southwestern Medical Center
- Dallas, TX 75390-9148 United States
The pain game
Abstract
The safety problems that brought down Vioxx have tainted a whole class of drugs. Meredith Wadman examines their chances of a comeback.
Few were surprised this spring when an advisory panel to the US Food and Drug Administration (FDA) trounced Merck's Arcoxia (etoricoxib) in a 20–1 vote. The painkiller was, after all, a 'COX2 inhibitor' — a relative of Vioxx (rofecoxib), the Merck pill that was pulled from global markets in 2004 for increasing the risk of heart attacks and strokes.
To read this story in full you will need to login or make a payment (see right).
